Cargando…
Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study
PURPOSE: The Quality of Life Alzheimer’s Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness analyses, utilities based on the EQ-5D are often required. We report a new mapping algorith...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952290/ https://www.ncbi.nlm.nih.gov/pubmed/33068236 http://dx.doi.org/10.1007/s11136-020-02670-8 |
_version_ | 1783663696007921664 |
---|---|
author | Rombach, Ines Iftikhar, Marvi Jhuti, Gurleen S. Gustavsson, Anders Lecomte, Pascal Belger, Mark Handels, Ron Castro Sanchez, Amparo Y. Kors, Jan Hopper, Louise Olde Rikkert, Marcel Selbæk, Geir Stephan, Astrid Sikkes, Sietske A. M. Woods, Bob Gonçalves-Pereira, Manuel Zanetti, Orazio Ramakers, Inez H. G. B. Verhey, Frans R. J. Gallacher, John Actifcare Consortium LeARN Consortium Landeiro, Filipa Gray, Alastair M. |
author_facet | Rombach, Ines Iftikhar, Marvi Jhuti, Gurleen S. Gustavsson, Anders Lecomte, Pascal Belger, Mark Handels, Ron Castro Sanchez, Amparo Y. Kors, Jan Hopper, Louise Olde Rikkert, Marcel Selbæk, Geir Stephan, Astrid Sikkes, Sietske A. M. Woods, Bob Gonçalves-Pereira, Manuel Zanetti, Orazio Ramakers, Inez H. G. B. Verhey, Frans R. J. Gallacher, John Actifcare Consortium LeARN Consortium Landeiro, Filipa Gray, Alastair M. |
author_sort | Rombach, Ines |
collection | PubMed |
description | PURPOSE: The Quality of Life Alzheimer’s Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness analyses, utilities based on the EQ-5D are often required. We report a new mapping algorithm to obtain EQ-5D indices when only QoL-AD data are available. METHODS: Different statistical models to estimate utility directly, or responses to individual EQ-5D questions (response mapping) from QoL-AD, were trialled for patient-rated and proxy-rated questionnaires. Model performance was assessed by root mean square error and mean absolute error. RESULTS: The response model using multinomial regression including age and sex, performed best in both the estimation dataset and an independent dataset. CONCLUSIONS: The recommended mapping algorithm allows researchers for the first time to estimate EQ-5D values from QoL-AD data, enabling cost-utility analyses using datasets where the QoL-AD but no utility measures were collected. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11136-020-02670-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7952290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-79522902021-03-28 Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study Rombach, Ines Iftikhar, Marvi Jhuti, Gurleen S. Gustavsson, Anders Lecomte, Pascal Belger, Mark Handels, Ron Castro Sanchez, Amparo Y. Kors, Jan Hopper, Louise Olde Rikkert, Marcel Selbæk, Geir Stephan, Astrid Sikkes, Sietske A. M. Woods, Bob Gonçalves-Pereira, Manuel Zanetti, Orazio Ramakers, Inez H. G. B. Verhey, Frans R. J. Gallacher, John Actifcare Consortium LeARN Consortium Landeiro, Filipa Gray, Alastair M. Qual Life Res Article PURPOSE: The Quality of Life Alzheimer’s Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness analyses, utilities based on the EQ-5D are often required. We report a new mapping algorithm to obtain EQ-5D indices when only QoL-AD data are available. METHODS: Different statistical models to estimate utility directly, or responses to individual EQ-5D questions (response mapping) from QoL-AD, were trialled for patient-rated and proxy-rated questionnaires. Model performance was assessed by root mean square error and mean absolute error. RESULTS: The response model using multinomial regression including age and sex, performed best in both the estimation dataset and an independent dataset. CONCLUSIONS: The recommended mapping algorithm allows researchers for the first time to estimate EQ-5D values from QoL-AD data, enabling cost-utility analyses using datasets where the QoL-AD but no utility measures were collected. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11136-020-02670-8) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-10-17 2021 /pmc/articles/PMC7952290/ /pubmed/33068236 http://dx.doi.org/10.1007/s11136-020-02670-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Rombach, Ines Iftikhar, Marvi Jhuti, Gurleen S. Gustavsson, Anders Lecomte, Pascal Belger, Mark Handels, Ron Castro Sanchez, Amparo Y. Kors, Jan Hopper, Louise Olde Rikkert, Marcel Selbæk, Geir Stephan, Astrid Sikkes, Sietske A. M. Woods, Bob Gonçalves-Pereira, Manuel Zanetti, Orazio Ramakers, Inez H. G. B. Verhey, Frans R. J. Gallacher, John Actifcare Consortium LeARN Consortium Landeiro, Filipa Gray, Alastair M. Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study |
title | Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study |
title_full | Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study |
title_fullStr | Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study |
title_full_unstemmed | Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study |
title_short | Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study |
title_sort | obtaining eq-5d-5l utilities from the disease specific quality of life alzheimer’s disease scale: development and results from a mapping study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952290/ https://www.ncbi.nlm.nih.gov/pubmed/33068236 http://dx.doi.org/10.1007/s11136-020-02670-8 |
work_keys_str_mv | AT rombachines obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT iftikharmarvi obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT jhutigurleens obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT gustavssonanders obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT lecomtepascal obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT belgermark obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT handelsron obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT castrosanchezamparoy obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT korsjan obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT hopperlouise obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT olderikkertmarcel obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT selbækgeir obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT stephanastrid obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT sikkessietskeam obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT woodsbob obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT goncalvespereiramanuel obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT zanettiorazio obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT ramakersinezhgb obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT verheyfransrj obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT gallacherjohn obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT actifcareconsortium obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT learnconsortium obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT landeirofilipa obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT grayalastairm obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy AT obtainingeq5d5lutilitiesfromthediseasespecificqualityoflifealzheimersdiseasescaledevelopmentandresultsfromamappingstudy |